Amgen relinquishes board appointment right at BeiGene; Hooper remains

BeOne Medicines Ltd.

Amgen gave up its right to designate a director to BeiGene's board under an amendment to the 2019 Share Purchase Agreement.
Anthony C. Hooper, Amgen's former designee, will continue serving as director on BeiGene's board until his term ends in 2025.
The amendment was effective January 30, 2023; Amgen cited BeiGene's global growth as the reason for relinquishing the right.
Amgen invested approximately $2.78 billion in BeiGene in 2019, receiving shares and board appointment rights.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BeOne Medicines Ltd. amended Amendment No. 3 to the Share Purchase Agreement with Amgen Inc. (effective 2023-01-30).

Action: amendment
Agreement: equity purchase
Counterparty: Amgen Inc.
Effective: 2023-01-30

Exact text from the filing

On January 30, 2023, on account of the Company’s global growth, Amgen elected to relinquish its right to appoint a designated director to the Company’s board of directors, pursuant to an Amendment No. 3 to the Share Purchase Agreement (the “Amendment”).

View on SEC.gov

Browse all material agreements →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.